A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified urinary FSH

References

• Gemzell CA, Diczfaluzy E, Tillinger KG. Human pituitary follicle-stimulating hormone. I: Clinical effect of a partly purified preparation. Ciba Found Colloq Endocrinol 1960; 13: 191
   Google Scholar
• Howies CM, MacNamee MC, Edwards RG. Follicular development and early luteal function of conception and non-conceptional cycles after human in vitro fertilization: endocrine correlates. Hum Reprod 1987; 2: 17–21
   PubMedGoogle Scholar
• Stanger J, Yovich JJ. Reduced in vitro fertilization of human oocyte from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985; 92: 385–93
   PubMedGoogle Scholar
• Homburg R, Armar NA, Eshel A, et al. Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Br Med J 1988; 297: 1024–6
   PubMed Web of Science ®Google Scholar
• Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinizing hormone, infertility and miscarriage. Lancet 1990; 336: 1141–4
   PubMed Web of Science ®Google Scholar
• Daya S, Gunby J, Hughes EG, et al. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization. Hum Reprod 1995; 10: 1392–6
   PubMed Web of Science ®Google Scholar
• Flamigni C, Venturoli S, Parasidi R. Induction of ovulation with human urinary FSH. 1980, 10th Congress Mundial de Fertilidad et Esterilidade, Madrid, Spain, Abstr. 358
   Google Scholar
• Shaw RW, Ndukwe G, Imoedemhe DAG, et al. Twin pregnancy after pituitary desensitization with LHRH agonist and pure FSH. Lancet 1985; ii: 506
   Google Scholar
• Le Cotonnec JY, Porchet HC, Beltrami V, Howies C. Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod 1993; 8: 1604–11
   PubMedGoogle Scholar
• Wikland M, Borg J, Hamberger L, Svalander P. Minimal monitoring and the use of subcutaneous FSH-HP administration. Hum Reprod 1994; 9: 1430–6
   PubMed Web of Science ®Google Scholar
• Loumaye E, Campbell R, Salat-Baroux J. Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians. Hum Reprod Update 1995; 1: 188–99
   PubMed Web of Science ®Google Scholar
• Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril 1995; 64: 855–6
   PubMedGoogle Scholar
• Bergh C, Howies CM, Borg K, et al. Recombinant human follicle stimulating hormone (r-FSH; Gonal-F) versus highly purified urinary FSH (Metrodin-HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 1997; 12: 2133–9
   PubMed Web of Science ®Google Scholar
• Frydman R, Avril C, Camier B, et al. A double-blind, randomised study comparing the efficacy of recombinant human follicle stimulating hormone (r-hFSH/Gonal-F) and highly purified urinary FSH (u-hFSH HP/Metrodin HP) in inducing superovulation in women undergoing assisted reproductive techniques (ART). 1998, ESHRE, Gothenburg, Sweden
   Google Scholar
• Oliveira JBA, Baruffi RLR, Mauri AL, et al. Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins. Hum Reprod 1997; 12: 2515–18
   PubMedGoogle Scholar
• Svalander P, Forsberg AS, Jakobsson AH, Wikland M. Factors of importance for the establishment of a successful program of intracytoplasmic sperm injection treatment for male infertility. Fertil Steril 1995; 63: 828–37
   PubMed Web of Science ®Google Scholar
• Out HJ, Driessen SGAJ, Mannaerts BMJL, Bennink HJTC. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997; 68: 138–42
   PubMed Web of Science ®Google Scholar
• Van den Eede B. ESHRE guide lines. Hum Reprod 1995; 10: 1246–71
   PubMedGoogle Scholar
• Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10: 2107–11
   PubMed Web of Science ®Google Scholar
• Lambert A, Talbot JA, Anobile CJ, Robertson WR. Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Mol Hum Reprod 1998; 4: 619–29
   PubMed Web of Science ®Google Scholar
• Matikainen T, De Leeuw R, Mannaerts B, Huhtaniemi I. Circulating bioactive and immuno-reactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin deficient subjects. Fertil Steril 1994; 61: 62–9
   PubMed Web of Science ®Google Scholar